一氧化氮前体药物与前列腺癌的研究进展  

Nitric Oxide-donor Drugs and Prostate Cancer:An Update

作　　者：陈烈钳 谭国斌[1] 陈合格[1] 柳建军[1] 

机构地区：[1]广东医学院泌尿外科研究室,湛江524001

出　　处：《肿瘤防治研究》2016年第2期162-166,共5页Cancer Research on Prevention and Treatment

基　　金：国家自然科学基金(81272833)

摘　　要：前列腺癌是男性最常见的肿瘤之一。一氧化氮(nitric oxide,NO)作为生物信使或效应分子在体内发挥重要的生理作用,且其体内水平异常与多种疾病的发生和发展密切相关。因此,一氧化氮前体型药物的研究备受关注。一些NO前体药物已被证实具有良好的抗肿瘤活性,显示出广泛的临床应用潜力和价值。目前,NO前体药物中显示出显著抗肿瘤效应的主要有有机硝酸酯、硝普盐、S-亚硝基硫醇和偶氮二醇烯鎓盐等。一氧化氮前体药可通过靶向释放NO,直接杀伤肿瘤细胞、诱导肿瘤细胞凋亡、增强免疫系统作用、削弱肿瘤细胞增殖及侵袭能力,并抑制其转移,提高肿瘤细胞对放化疗的敏感度,从而发挥抗肿瘤作用。本文就近年来NO前体药物对前列腺癌作用的研究进展作一综述。Prostate cancer is one of the most common cancers in the male. Nitric oxide （NO）, a crucial biological messenger and effector molecule, is involved in the regulation of various physiological functions and closely related to many diseases when its level is abnormal in the body. Now the research on NO-donor drugs has drawn more and more attention. A few NO-donor drugs have been confirmed to have favorable anticancer activity and have the potential for further clinical development of anticancer therapy. Currently some NO-donor drugs have exhibited significant anti-tumor effect, including organic nitrates, nitroprusside, S-nitrosothiols, diazeniumdiolates and so on. By targeting NO release, NO donors drugs can directly kill tumor cells, induce apoptosis, strengthen the immune system, as well as inhibit tumor proliferation, invasion and metastasis, and enhance radio- and chemo-sensitivity of tumor cells. In this paper, recent progresses in the research on NO-donor drugs in prostate cancer are reviewed.

关 键 词：一氧化氮前体药物 前列腺癌 治疗 

分 类 号：R737[医药卫生—肿瘤]